Clene Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLNN research report →
Range $50 – $50
Price Chart
About the company
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies.
- CEO
- Robert Etherington
- IPO
- 2018
- Employees
- 78
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on CLNN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $49.45M
- P/E
- -1.09
- Fwd P/E
- 1.69
- PEG
- 0.53
- P/S
- 251.03
- P/B
- -1.93
- EV/EBITDA
- -2.23
- Div Yield
- 0.00%
- Gross Margin
- -110.15%
- Op Margin
- -10304.57%
- Net Margin
- -20059.90%
- ROE
- 214.97%
- ROIC
- -104.55%
Latest fiscal year · YoY change
- Revenue
- $200.00K-41.5%
- Gross Profit
- $157.00K-42.3%
- Op Income
- $-23,083,000
- Net Income
- $-26,173,000+33.6%
- EPS
- $-2.65+53.3%
- OCF Growth
- +13.0%
- FCF Growth
- +12.9%
- 52W High
- $13.50
- 52W Low
- $3.25
- 50D MA
- $4.35
- 200D MA
- $5.40
- Beta
- 0.92
- RSI (14)
- 42
- Avg Volume
- 100.58K
No earnings-call transcripts are available for CLNN yet.
- Free Float
- 75.0%
- Shares Outstanding
- 12.78M
- Float Shares
- 9.59M
of shares held by institutions
29 13F filers
Buy/sell ratio 5.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Empery Asset Management, LP | 916.53K | ▲ 916.53K |
| Scoggin Management LP | 600.00K | ▲ 300.00K |
| Boxer Capital Management, LLC | 477.51K | 0 |
| Ensign Peak Advisors, Inc | 348.06K | ▲ 90.19K |
| Vanguard Capital Management LLC | 333.71K | ▲ 25.48K |
| Vanguard Group Inc | 222.91K | ▲ 21.93K |
| Geode Capital Management, LLC | 102.22K | ▲ 6.34K |
| Blackrock, Inc. | 61.56K | ▲ 27.76K |
| Vanguard Fiduciary Trust Co | 57.77K | ▲ 14.05K |
| Lunt Capital Management, Inc. | 52.26K | 0 |
| Parsons Capital Management Inc/Ri | 37.24K | 0 |
| Peak6 LLC | 30.01K | ▼ 20.00K |
Held by 24 ETFs
Biggest fund positions in CLNN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | MATLIN DAVID J | other | 434,451 |
| Sep 16, 26 | Etherington Robert Dee | other | 15,244 |
| Sep 16, 26 | Mosca Alison | other | 198,171 |
| Aug 13, 26 | Kiernan Matthew | other | 3,195 |
| Aug 13, 26 | Desai Arjun JJ | other | 3,674 |
| Aug 13, 26 | Mosca Alison | other | 4,872 |
| Aug 13, 26 | MATLIN DAVID J | other | 6,230 |
| Aug 13, 26 | Jacobovitz Shalom | other | 4,752 |
| Aug 13, 26 | Gay Jonathon | other | 3,794 |
| Aug 13, 26 | McLaughlin Vallerie | other | 3,514 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLNN coverage
Recent articles, reports, and earnings notes.
No research on CLNN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLNN report →Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
marketbeat.com · Oct 2
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of “Moderate Buy” from Brokerages
defenseworld.net · Sep 30
Clene to Present at Upcoming Investor Conferences
globenewswire.com · Sep 22
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
globenewswire.com · Sep 21
Clene Announces $4 Million Registered Direct Offering
globenewswire.com · Sep 15
Canopy Growth (NASDAQ:CGC) vs. Clene (NASDAQ:CLNN) Financial Comparison
defenseworld.net · Sep 10
Clene to Present at Upcoming September Investor Conferences
globenewswire.com · Sep 3
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
marketbeat.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.